CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for International Stem Cell Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

International Stem Cell Corp
9745 BUSINESSPARK AVENUE
Phone: (760) 940-6383p:760 940-6383 SAN DIEGO, CA  92131  United States Ticker: ISCOISCO
Business Summary
International Stem Cell Corporation is a clinical-stage biotechnology company that is focused on therapeutic and biomedical product development. The Company is primarily a research and development company, for the therapeutic market, which has focused on advancing potential clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central nervous system and liver diseases. The Company's products are based on human cell culture and a type of pluripotent stem cells and hpSCs. The Company's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC), which develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
6770 Blank checks
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Co-Chairman of the Board, Chief Executive Officer AndreySemechkin 63 12/1/2013 12/30/2008
Independent Co-Chairman of the Board, CEO and President of SIS, Inc. Donald A.Wright 76 12/1/2013 3/1/2007
Executive Vice President, Chief Scientific Officer RussellKern 37 12/1/2022 10/14/2008
Independent Investor Paul V.Maier 76 7/19/2007 7/19/2007

Business Names
Business Name
Cyto Therapeutics Pty. Ltd.
International Stem Cell Corporation
ISCO
Lifeline Cell Technology, LLC
Lifeline Skincare, Inc

General Information
Number of Employees: 29 (As of 12/31/2023)
Outstanding Shares: 8,004,389 (As of 8/8/2024)
Shareholders: 632
Stock Exchange: OTC
Federal Tax Id: 020449409
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024